These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8145601)

  • 1. Substitution laws, insurance coverage, and generic drug use.
    Anis AH
    Med Care; 1994 Mar; 32(3):240-56. PubMed ID: 8145601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives. Drug formularies pose legal threat to providers.
    Moskowitz DB
    Faulkner Grays Med Health; 1995 Feb; 49(6):suppl 1-4. PubMed ID: 10139750
    [No Abstract]   [Full Text] [Related]  

  • 6. Medicaid prescription drug coverage: state efforts to control costs.
    Gencarelli DM
    NHPF Issue Brief; 2003 May; (790):1-17. PubMed ID: 12751504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults.
    Pauly NJ; Brown JD
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1162-70. PubMed ID: 26679965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Employers push to manage prescription drug costs.
    Frieden J
    Bus Health; 1992 May; 10(6):43-6, 48, 50. PubMed ID: 10119119
    [No Abstract]   [Full Text] [Related]  

  • 9. Are private physicians more likely to veto generic substitution of prescribed pharmaceuticals?
    Granlund D
    Soc Sci Med; 2009 Dec; 69(11):1643-50. PubMed ID: 19815322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective strategies for managing pharmacy benefits.
    Jacobson D
    Healthc Financ Manage; 2001 Mar; 55(3):41-2. PubMed ID: 11258270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating and Preventing HIV with Generic Drugs - Barriers in the United States.
    Martin EG; Schackman BR
    N Engl J Med; 2018 Jan; 378(4):316-319. PubMed ID: 29365306
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans.
    Johnsrud M; Lawson KA; Shepherd MD
    J Manag Care Pharm; 2007 Mar; 13(2):122-34. PubMed ID: 17330973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
    J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The patients' cost of the montelukast therapy due to the generic substitution].
    Répásy B; Endrei D; Zemplényi A; Ágoston I; Boncz I
    Orv Hetil; 2018 Apr; 159(17):682-687. PubMed ID: 29681174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying widely covered drugs and drug coverage variation among Medicare part D formularies.
    Tseng CW; Mangione CM; Brook RH; Keeler E; Dudley RA
    JAMA; 2007 Jun; 297(23):2596-602. PubMed ID: 17579228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
    Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
    Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ontario's plunging price-caps on generics: deeper dives may drown some drugs.
    Anis A; Harvard S; Marra C
    Open Med; 2011; 5(3):e149-52. PubMed ID: 22046229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of price-cap regulations on market entry by generic pharmaceutical firms.
    Zhang W; Sun H; Guh D; Anis AH
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):231-238. PubMed ID: 27936981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
    McManus P; Birkett DJ; Dudley J; Stevens A
    Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic grand rounds: the economics of the new medicare drug benefit: implications for people with mental illnesses.
    Donohue JM
    Psychiatr Serv; 2005 Jun; 56(6):645-7. PubMed ID: 15939937
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.